Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Aug 24;91(18):e00905-17.
doi: 10.1128/JVI.00905-17. Print 2017 Sep 15.

Protection against HIV Acquisition in the RV144 Trial

Ronald C Desrosiers  1
Affiliations
Comment

Protection against HIV Acquisition in the RV144 Trial

Ronald C Desrosiers. J Virol. .

Abstract

Differences of opinion regarding whether there may, or may not, have been protective efficacy in the RV144 vaccine trial have important societal implications.

Keywords: HIV vaccine; efficacy trials.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(Left panel) Kaplan-Meier acquisition curve from the RV144/Thai trial. Data are from the one analysis (the modified intention-to-treat group) of three that showed a P value of less than 0.05 with the tests used. (Reprinted from The New England Journal of Medicine with permission of the publisher [see Fig. 2C in reference 1].) The circled data represent the anomalous nonlinear increase in acquisition in the placebo group in the first year of the trial that was responsible for most or all of the differences in HIV-1 acquisition. (Right panel) Linear rates of HIV-1 acquisition in both the placebo and vaccine groups in the HVTN505 trial. CI, confidence interval. (Reprinted from The New England Journal of Medicine with permission of the publisher [see Fig. 2B in reference 5].)
FIG 2
FIG 2
IgG antibodies as a correlate of immunity in the RV144/Thai trial. (Reprinted from The New England Journal of Medicine with permission of the publisher [see Fig. 2A in reference 8].)
See this image and copyright information in PMC

Comment on

References

    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220. doi:10.1056/NEJMoa0908492. - DOI - PubMed
    1. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. 2015. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med 7:310rv7. doi:10.1126/scitranslmed.aac7732. - DOI - PMC - PubMed
    1. Fauci AS. 2017. Towards an HIV vaccine: a scientific journey. https://www.youtube.com/watch?v=8iHK3B-g7GI Accessed June 2017.
    1. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. 2011. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 203:969–975. doi:10.1093/infdis/jiq152. - DOI - PMC - PubMed
    1. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369:2083–2092. doi:10.1056/NEJMoa1310566. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources